Evotec SE announces third quarter results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy EVO?
Source: SeekingAlpha
Q3 Financial Performance: Evotec SE reported a 7.1% decrease in group revenues to €535.1 million for Q3, with a 12.3% decline in D&PD revenues attributed to soft demand in early drug discovery services.
Adjusted EBITDA and Costs: The adjusted Group EBITDA was €(16.9) million, impacted by underutilization and high fixed costs in the D&PD segment, along with expenses related to the JEB Toulouse facility ramp-up.
Future Outlook: The company targets a compound annual growth rate (CAGR) of 8-12% for group revenues from 2024 to 2028, with an expected adjusted EBITDA margin above 20% by 2028.
2025 Guidance: Evotec confirmed its guidance for 2025, projecting group revenues between €760-800 million and adjusted Group EBITDA of €30-50 million, alongside R&D expenditures of €40-50 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVO
Wall Street analysts forecast EVO stock price to rise
3 Analyst Rating
2 Buy
0 Hold
1 Sell
Moderate Buy
Current: 2.420
Low
5.00
Averages
6.00
High
7.00
Current: 2.420
Low
5.00
Averages
6.00
High
7.00
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evotec's Biologics Unit Selected by US Government
- Government Collaboration: Evotec's biologics unit, Just - Evotec Biologics, has been selected by the US government, indicating an enhancement of the company's influence in the biopharmaceutical sector and potentially laying the groundwork for future project collaborations.
- Market Potential: This selection could provide Evotec with new revenue streams, bolstering its competitiveness in the biopharmaceutical market, especially as government contracts become increasingly significant.
- Strategic Implications: Collaborating with the US government not only enhances Evotec's brand image but may also attract other potential clients, further expanding its market share.
- R&D Support: This selection could provide Evotec with additional funding for research and development, aiding its innovation and technological advancements in the biopharmaceutical field.
See More
Evotec and BMS Initiate Phase 1 Clinical Trial for Kidney Cancer Treatment
- Clinical Trial Launch: The initiation of Phase 1 clinical trial for BMS-986506 in advanced clear cell renal cell carcinoma marks a significant advancement in the strategic collaboration between Evotec and BMS, potentially establishing a new treatment paradigm for kidney cancer.
- Milestone Payment: Evotec will receive a $10 million milestone payment as a result of this clinical progression, which not only strengthens the company's financial position but also reflects its technological prowess in the protein degradation field.
- Technology Validation: The trial validates Evotec's capabilities in high-performance multi-omics screening and AI-supported data analytics, showcasing its potential in developing novel molecular glue drugs that could reshape cancer treatment standards.
- Deepening Strategic Collaboration: Since the partnership with BMS began in 2018, Evotec has been advancing molecular glue drug development through its PanOmics and PanHunter platforms, aiming to address significant unmet medical needs and further solidify its leadership in the biopharmaceutical sector.
See More
Investigation Launched into Evotec SE for Potential Investor Claims
- Restructuring Announcement: On March 10, 2026, Evotec SE announced its 'Horizon' restructuring initiative, projecting revenues of €700 million to €780 million and adjusted EBITDA between €0 and €40 million for 2026, indicating a significant transition that may impact investor confidence.
- Cash Restructuring Charges: The company expects approximately €100 million in cash restructuring charges over the 2026-2028 period, which could exert financial pressure on the company and negatively affect its stock performance.
- Legal Compliance Investigation: Johnson Fistel, PLLP is investigating whether Evotec complied with federal securities laws, and any findings of wrongdoing could lead to legal liabilities for the company, further exacerbating investor loss risks.
- Investor Rights Protection: Johnson Fistel, PLLP, a recognized shareholder rights law firm, has successfully recovered approximately $90.725 million for clients, demonstrating its capability in protecting investor rights, which may encourage more affected investors to join the investigation.
See More
Evotec Launches Strategic Transformation Initiative 'Horizon'
- Strategic Transformation Plan: Evotec has announced a new strategic transformation initiative called 'Horizon,' aimed at reshaping its operating model and improving margins, with expectations to significantly enhance performance in the drug discovery and preclinical development market by 2027.
- Organizational Simplification and Layoffs: As part of the transformation, Evotec plans to simplify its organizational structure, reducing its global footprint from 19 locations to 10, which is expected to affect up to 800 positions, thereby strengthening scientific collaboration and innovation capabilities.
- Financial Impact and Cost Savings: The initiative is projected to generate approximately €75 million (around $87.3 million) in annual run-rate cost savings by 2027, but the implementation will incur restructuring-related cash charges of about €100 million, along with potential non-cash impairment charges.
- Updated Financial Outlook: Evotec anticipates preliminary fiscal 2025 sales of about €788 million and adjusted EBITDA of roughly €41 million, with 2026 revenue expected between €700 million and €780 million, reflecting the challenges of a transition year during the restructuring process.
See More
U.S. Stocks Mixed in Morning Trading
- Dow Jones Decline: On Tuesday, the Dow Jones fell approximately 0.07% to 47,709.07 points after market opening, reflecting cautious sentiment towards economic data that may impact investor confidence.
- NASDAQ Gains: In contrast, the NASDAQ rose by 0.13% to 22,724.49 points, indicating a relatively strong performance in tech stocks, which could attract more capital inflows into this sector.
- United Natural Foods' Mixed Results: Shares of United Natural Foods, Inc. (NYSE:UNFI) dropped around 7% on Tuesday, as its quarterly earnings of 62 cents per share exceeded the analyst consensus of 51 cents, yet its sales of $7.947 billion fell short of the $8.108 billion estimate, highlighting market challenges.
- Commodity Market Fluctuations: Oil prices fell by 8% to $87.24, while gold increased by 2.3% to $5,221.20, reflecting heightened demand for safe-haven assets, which may also impact the profitability of related companies.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Evotec's Biologics Unit Selected by US Government
- Government Collaboration: Evotec's biologics unit, Just - Evotec Biologics, has been selected by the US government, indicating an enhancement of the company's influence in the biopharmaceutical sector and potentially laying the groundwork for future project collaborations.
- Market Potential: This selection could provide Evotec with new revenue streams, bolstering its competitiveness in the biopharmaceutical market, especially as government contracts become increasingly significant.
- Strategic Implications: Collaborating with the US government not only enhances Evotec's brand image but may also attract other potential clients, further expanding its market share.
- R&D Support: This selection could provide Evotec with additional funding for research and development, aiding its innovation and technological advancements in the biopharmaceutical field.
See More
Evotec and BMS Initiate Phase 1 Clinical Trial for Kidney Cancer Treatment
- Clinical Trial Launch: The initiation of Phase 1 clinical trial for BMS-986506 in advanced clear cell renal cell carcinoma marks a significant advancement in the strategic collaboration between Evotec and BMS, potentially establishing a new treatment paradigm for kidney cancer.
- Milestone Payment: Evotec will receive a $10 million milestone payment as a result of this clinical progression, which not only strengthens the company's financial position but also reflects its technological prowess in the protein degradation field.
- Technology Validation: The trial validates Evotec's capabilities in high-performance multi-omics screening and AI-supported data analytics, showcasing its potential in developing novel molecular glue drugs that could reshape cancer treatment standards.
- Deepening Strategic Collaboration: Since the partnership with BMS began in 2018, Evotec has been advancing molecular glue drug development through its PanOmics and PanHunter platforms, aiming to address significant unmet medical needs and further solidify its leadership in the biopharmaceutical sector.
See More
Investigation Launched into Evotec SE for Potential Investor Claims
- Restructuring Announcement: On March 10, 2026, Evotec SE announced its 'Horizon' restructuring initiative, projecting revenues of €700 million to €780 million and adjusted EBITDA between €0 and €40 million for 2026, indicating a significant transition that may impact investor confidence.
- Cash Restructuring Charges: The company expects approximately €100 million in cash restructuring charges over the 2026-2028 period, which could exert financial pressure on the company and negatively affect its stock performance.
- Legal Compliance Investigation: Johnson Fistel, PLLP is investigating whether Evotec complied with federal securities laws, and any findings of wrongdoing could lead to legal liabilities for the company, further exacerbating investor loss risks.
- Investor Rights Protection: Johnson Fistel, PLLP, a recognized shareholder rights law firm, has successfully recovered approximately $90.725 million for clients, demonstrating its capability in protecting investor rights, which may encourage more affected investors to join the investigation.
See More
Evotec Launches Strategic Transformation Initiative 'Horizon'
- Strategic Transformation Plan: Evotec has announced a new strategic transformation initiative called 'Horizon,' aimed at reshaping its operating model and improving margins, with expectations to significantly enhance performance in the drug discovery and preclinical development market by 2027.
- Organizational Simplification and Layoffs: As part of the transformation, Evotec plans to simplify its organizational structure, reducing its global footprint from 19 locations to 10, which is expected to affect up to 800 positions, thereby strengthening scientific collaboration and innovation capabilities.
- Financial Impact and Cost Savings: The initiative is projected to generate approximately €75 million (around $87.3 million) in annual run-rate cost savings by 2027, but the implementation will incur restructuring-related cash charges of about €100 million, along with potential non-cash impairment charges.
- Updated Financial Outlook: Evotec anticipates preliminary fiscal 2025 sales of about €788 million and adjusted EBITDA of roughly €41 million, with 2026 revenue expected between €700 million and €780 million, reflecting the challenges of a transition year during the restructuring process.
See More
U.S. Stocks Mixed in Morning Trading
- Dow Jones Decline: On Tuesday, the Dow Jones fell approximately 0.07% to 47,709.07 points after market opening, reflecting cautious sentiment towards economic data that may impact investor confidence.
- NASDAQ Gains: In contrast, the NASDAQ rose by 0.13% to 22,724.49 points, indicating a relatively strong performance in tech stocks, which could attract more capital inflows into this sector.
- United Natural Foods' Mixed Results: Shares of United Natural Foods, Inc. (NYSE:UNFI) dropped around 7% on Tuesday, as its quarterly earnings of 62 cents per share exceeded the analyst consensus of 51 cents, yet its sales of $7.947 billion fell short of the $8.108 billion estimate, highlighting market challenges.
- Commodity Market Fluctuations: Oil prices fell by 8% to $87.24, while gold increased by 2.3% to $5,221.20, reflecting heightened demand for safe-haven assets, which may also impact the profitability of related companies.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
